title: Dose reduction of epoetin-alpha in the prevention of chemotherapy-induced anaemia.
abstract: BACKGROUND
  Anaemia during chemotherapy is often left untreated. Erythropoiesis-stimulating agents are frequently used to treat overt anaemia. Their prophylactic use, however, remains controversial and raises concerns about cost-effectiveness. Therefore, we assessed the efficacy of a dose-reduction schedule in anaemia prophylaxis.
  
  
  METHODS
  The study included patients with untreated solid tumours about to receive platinum-based chemotherapy and had haemoglobin (Hb) levels ≥11 g/dL. Epoetin-α was administered at a dose level of 3 × 10,000 U weekly as soon as Hb descended to < 13 g/dL. Dose reductions to 3 × 4,000 U and 3 × 2,000 U weekly were planned in 4-week intervals if Hb stabilised in the range of 11-13 g/dL. Upon ascending to ≥13 g/dL, epoetin was discontinued. Iron supplements of 100 mg intravenous doses were given weekly. Of 37 patients who enrolled, 33 could be evaluated.
  
  
  CONCLUSIONS
  Their median Hb level was 13.7 (10.9-16.2) g/dL at baseline and descended to 11.0 (7.4-13.8) g/dL by the end of chemotherapy. Anaemia (Hb < 10 g/dL) was prevented in 24 patients (73%). The mean dose requirement for epoetin-α was 3 × 5,866 U per week per patient, representing a dose reduction of 41%. Treatment failed in nine patients (27%), in part due to epoetin-α resistance in four (12%) and blood transfusion in three (9%) patients.
  
  
  CONCLUSIONS
  Dose reduction was as effective as fixed doses in anaemia prophylaxis but reduced the amount of prescribed epoetin substantially.
authors.affiliation: Centre Pluridisciplinaire d'Oncologie, University Hospital-CHUV BH06, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
authors.forename: François
authors.initials: F
authors.lastname: Lüthi
authors.forename: Miklos
authors.initials: M
authors.lastname: Pless
authors.forename: Serge
authors.initials: S
authors.lastname: Leyvraz
authors.forename: Beat
authors.initials: B
authors.lastname: Biedermann
authors.forename: Emilie
authors.initials: E
authors.lastname: Müller
authors.forename: Richard
authors.initials: R
authors.lastname: Hermann
authors.forename: Christian
authors.initials: C
authors.lastname: Monnerat
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced* / Q000517:prevention & control*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa